JUNEL 1.5/30
Clinical safety rating
cautionComprehensive clinical and safety monograph for JUNEL 1.5/30 (JUNEL 1.5/30).
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.
| Metabolism | Hepatic: ethinyl estradiol primarily via CYP3A4; norethindrone via reduction, sulfate and glucuronide conjugation. First-pass metabolism extensive. Enterohepatic recirculation. |
| Excretion | Ethinyl estradiol (EE) and norethindrone (NET) are excreted in urine (40-60% as metabolites) and feces (20-30% as metabolites). NET is also excreted in bile and undergoes enterohepatic recirculation. |
| Half-life | EE: terminal half-life ~17 ± 8 hours; NET: terminal half-life ~8 ± 1 hours. Steady-state achieved within ~2-3 cycles. |
| Protein binding | EE: ~97% bound to albumin; NET: ~61% bound to albumin, ~36% bound to SHBG. |
| Volume of Distribution | EE: ~6.5 L/kg; NET: ~4 L/kg. Reflects extensive tissue distribution. |
| Bioavailability | EE: ~40-45% (oral); NET: ~64% (oral) due to first-pass metabolism. |
| Onset of Action | Oral: contraceptive effect requires 7 days of continuous dosing if started on day 1 of menses; immediate if started on day 1. |
| Duration of Action | Oral: 24-hour dosing interval; contraceptive protection persists with missed pill up to 12 hours. |
| Molecular Weight | 340.5 |
| Action Class | Oral Contraceptive; Estrogen-Progestin Combination |
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal disease or acute renal failure due to potential fluid retention. |
| Liver impairment | Contraindicated in acute hepatic disease, hepatic adenomas, or history of cholestatic jaundice with prior oral contraceptive use. For Child-Pugh A (mild impairment), no adjustment; for Child-Pugh B or C (moderate to severe), contraindicated. |
| Pediatric use | Safety and efficacy not established in pediatric patients; use only after menarche and as per adult dosing if post-menarche. |
| Geriatric use | Not indicated for use in postmenopausal women. No dose adjustment necessary if used in women over 40 years who are premenopausal and not at increased risk of cardiovascular disease; however, consider lower dose formulations for women over 35 who smoke or have other risk factors. |
| 1st trimester | Contraindicated due to risk of congenital anomalies (e.g., neural tube defects, cardiovascular malformations) associated with estrogen/progestin exposure. |
| 2nd trimester | Contraindicated; may cause fetal harm including masculinization of female fetuses due to androgenic activity of norethindrone. |
| 3rd trimester | Contraindicated; risk of fetal reproductive tract abnormalities and potential long-term effects. |
Clinical note
Comprehensive clinical and safety monograph for JUNEL 1.5/30 (JUNEL 1.5/30).
| Placental transfer | Crosses the placenta; norethindrone acetate and ethinyl estradiol are detectable in fetal tissues. |
| Breastfeeding | Excreted in small amounts into breast milk; may reduce milk production and quality. Use only if benefits outweigh risks; monitor infant for jaundice and breast enlargement. |
| Lactation Rating | L3 (Moderately Safe) - limited data suggest minimal risk, but caution advised. |
| Teratogenic Risk | FDA Pregnancy Category X. Postmarketing studies have not identified an increased risk of major birth defects or miscarriages with combined hormonal contraceptives (CHCs) prior to pregnancy or inadvertently during early pregnancy. However, CHCs are contraindicated during pregnancy because they provide no benefit and may cause fetal harm. First trimester: No increased risk of congenital anomalies from inadvertent use. Second and third trimesters: Administration during pregnancy has been associated with an increased risk of adverse outcomes including hepatotoxicity (jaundice, cholestasis), estrogen-induced fetal masculinization of female genitalia, and potential long-term effects from androgen exposure. Use is contraindicated once pregnancy is confirmed. |
| Fetal Monitoring | Monitor liver function tests, blood pressure, renal function, and glucose tolerance in pregnant patients inadvertently exposed. Assess for signs of thromboembolic events, hyperkalemia, or hepatic dysfunction. Perform fetal ultrasound for growth and anatomy if exposure occurs during organogenesis. |
| Fertility Effects | Junel 1.5/30 suppresses ovulation as a primary mechanism of action. Fertility returns to baseline within 1-2 cycles after discontinuation; no permanent impairment of fertility has been documented. Transient menstrual irregularities may occur upon cessation. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially >35 years) and with smoking intensity. Women over 35 who smoke should not use this product.
| Common Effects | Nausea, Headache, Breast tenderness, Weight changes, Irregular uterine bleeding, Mood changes, Acne |
| Serious Effects | Venous thromboembolism (deep vein thrombosis, pulmonary embolism), Arterial thromboembolism (myocardial infarction, stroke), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Cerebrovascular events, Retinal thrombosis |
Known or suspected pregnancyThrombophlebitis or thromboembolic disordersHistory of deep vein thrombosis or pulmonary embolismCerebrovascular or coronary artery diseaseKnown or suspected carcinoma of the breastKnown or suspected estrogen-dependent neoplasiaUndiagnosed abnormal genital bleedingCholestatic jaundice of pregnancy or jaundice with prior pill useHepatic adenoma or carcinomaAge > 35 and smoking ≥ 15 cigarettes/day
| Precautions | Increased risk of thromboembolic disorders (DVT, PE, stroke, MI), especially in smokers >35 years. Hepatic neoplasia, gallbladder disease, hypertension, carbohydrate and lipid effects. Use caution with prediabetes/diabetes, migraine, SLE, hereditary angioedema. Discontinue if jaundice, visual disturbances, or suspected pregnancy. Do not use before menarche. |
| Food/Dietary | No specific food interactions require restriction. Grapefruit juice may slightly increase ethinyl estradiol levels, but not clinically significant. Avoid St. John's Wort as it may reduce contraceptive efficacy. |
| Clinical Pearls | Junel 1.5/30 is a monophasic oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for contraception. The pill-free interval during the placebo week may trigger withdrawal bleeding. Consistent timing is crucial; a delay of more than 3 hours in taking the active pill requires backup contraception for 7 days. Consider potential drug interactions with hepatic enzyme inducers (e.g., rifampin, carbamazepine) that may reduce efficacy. Monitor blood pressure and liver function periodically. |
| Patient Advice | Take one pill daily at the same time, starting on the first day of your menstrual period. · If you miss a pill, follow the package insert instructions: if missed for less than 12 hours, take it immediately and continue; if missed for more than 12 hours, take the last missed pill and use backup contraception for 7 days. · Common side effects include nausea, breast tenderness, and spotting, especially in the first few months. · Smoking increases the risk of serious cardiovascular side effects, especially in women over 35 years old. · If you experience severe headache, chest pain, leg pain, or vision changes, seek medical attention immediately. |
Loading safety data…